Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium)

• Status: Completed
• Trial end date: 2006-07-18
• Target enrollment: 0
• Participant gender: All

Summary

This study is requested by PMDA to confirm the optimal dose for THR (total hip replacement).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Fondaparinux; PENTA

Criteria

Inclusion Criteria:

• Patients undergoing either an elective primary THR (total hip replacement) surgery or a revision of a THR.

Exclusion Criteria:

• Active, clinically significant bleeding (excluding drainage).